- Home
- SBFM vs XRTX Comparison
SBFM vs XRTX Comparison
Compare SBFM & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBFM | XRTX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.9M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SBFM | XRTX |
|---|---|---|
| Price | $0.80 | $1.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 125.0K | ★ 404.2K |
| Earning Date | 04-03-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,305,891.00 | N/A |
| Revenue This Year | $40.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.25 | $0.35 |
| 52 Week High | $3.05 | $3.60 |
Technical Indicators
Market Signals| Indicator | SBFM | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.87 | 39.58 |
| Support Level | $0.27 | $1.59 |
| Resistance Level | $1.26 | $2.29 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 5.11 | 10.84 |
Price Performance
Historical ComparisonAbout SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.